Resident-Level Predictors of Dementia Pharmacotherapy at Long-Term Care Admission: The Impact of Different Drug Reimbursement Policies in Ontario and Saskatchewan: Predicteurs de la pharmacotherapie de la demence au niveau des residents lors de l'hospitalisation dans des soins de longue duree : l'impact de differentes politiques de remboursement des medicaments en Ontario et en Saskatchewan.

ABSTRACT:

Objectives

Cholinesterase inhibitors (ChEIs) and memantine are approved for Alzheimer disease in Canada. Regional drug reimbursement policies are associated with cross-provincial variation in ChEI use, but it is unclear how these policies influence predictors of use. Using standardized data from two provinces with differing policies, we compared resident-level characteristics associated with dementia pharmacotherapy at long-term care (LTC) admission.

Methods

Using linked clinical and administrative databases, we examined characteristics associated with dementia pharmacotherapy use among residents with dementia and/or significant cognitive impairment admitted to LTC facilities in Saskatchewan (more restrictive reimbursement policies; n = 10,599) and Ontario (less restr

SUBMITTER: Maclagan LC 

PROVIDER: S-EPMC7564697 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature